Please login to the form below
ipilimumab
This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
NICE turns down Opdivo for adjuvant melanoma therapy
Opdivo was approved for adjuvant treatment of melanoma on the back of data from the CheckMate-238 trial showing that it was superior to BMS’CTLA4 inhibitor Yervoy (ipilimumab) in reducing
Latest news
-
CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer
The committee said that while improvements in survival were seen in previously-untreated renal cell carcinoma patients given the combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab)
-
Pivotal data sets up Tecentriq filing in small cell lung cancer
Meanwhile, BMS recently filed a US marketing application for Opdivo in combination with its CTLA4 inhibitor Yervoy (ipilimumab) as a treatment for patients with progressive SCLC after two or more earlier
-
BMS presses go on Nektar combo pivotal trials, despite data debate
In February, BMS signed a $3.6bn deal to pair NKTR-214 with Opdivo and its CTLA4 inhibitor Yervoy (ipilimumab) in a host of tumour types, paying $1bn in cash upfront
-
Immuno-oncology at ASCO: survival data, combinations and new indications
The trial pairs Opdivo with chemotherapy as well as Opdivo plus CTLA4 inhibitor Yervoy (ipilimumab) versus chemotherapy in first-line NSCLC patients with low levels of PD-L1 expression - a group
-
Roche eyes September FDA verdict for triple NSCLC therapy
results thus far, and Bristol-Myers Squibb’s pairing of Opdivo (nivolumab) and Yervoy (ipilimumab).
More from news
Approximately 9 fully matching, plus 152 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
drug Yervoy (ipilimumab) in an early-stage trial.
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary clinical
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
ASCO 2015: What you missed in Chicago
Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Associate Scientific Director
-
Salary TBC
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Sudler London - Senior Medical Writer
-
Competitive
-
Sudler London - Account Director
-
Competitive
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Systematic Review Lead- London
-
Negotiable
Subscribe to our email news alerts
- Lucid limbers up for second annual sports day
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- Hanover Health launches award, Firstlight spins off healthcare arm and more
- J&J files ‘breakthrough’ bladder cancer drug in US
- Boehringer’s Corsico to be new GSK drug dev leader
- More tell, less sell: HCP-centric comms
PMHub
Complete HealthVizion
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
